Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven R Feldman

Showing results (311-320 of 1,293) with videos related to

Pageof 130
Sort By:
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|January 31, 2025
Commentary on "Factors Contributing to Poor Patient Reviews for Mohs Surgeons"Chenan A Huang, Steven R Feldman, Laura B Doerfler
Journal of Drugs in Dermatology : JDD|December 5, 2013
Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spraySteven R Feldman, Warren Winkelman, Eric Baum, et al.
Journal of Drugs in Dermatology : JDD|October 3, 2013
Adherence to ustekinumab in psoriasis patientsLaura F Sandoval, Karen E Huang, Steven R Feldman
Expert Opinion on Pharmacotherapy|November 17, 2020
An update on the impact of depression on the treatment of psoriasisKatheryn A Bell, Esther A Balogh, Steven R Feldman
Dermatology Online Journal|January 11, 2021
The dermatology residency application processSree S Kolli, Steven R Feldman, William W Huang
Dermatology and Therapy|June 10, 2021
Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of SecukinumabKatherine Houghton, Dhaval Patil, Braulio Gomez, et al.
Journal of the American Academy of Dermatology|February 8, 2020
The bandwagon effect increases acne treatment willingness in teenagersJeremy K Bray, E J Masicampo, Steven R Feldman
The Annals of Pharmacotherapy|May 19, 2022
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic DermatitisPatrick O Perche, Madison K Cook, Steven R Feldman
Journal of the American Academy of Dermatology|June 6, 2024
Atopic dermatitis may not confer clinically meaningful risk of inflammatory bowel disease or renal malignancyHannah Y Gantz, Jonathan D Greenzaid, Steven R Feldman
Clinical, Cosmetic and Investigational Dermatology|January 25, 2021
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque PsoriasisJeremy G Light, Jennifer J Su, Steven R Feldman
Pageof 130

Showing results (311-320 of 1,293) with videos related to

Sort By:
Pageof 130
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|January 31, 2025
Commentary on "Factors Contributing to Poor Patient Reviews for Mohs Surgeons"Chenan A Huang, Steven R Feldman, Laura B Doerfler
Journal of Drugs in Dermatology : JDD|December 5, 2013
Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spraySteven R Feldman, Warren Winkelman, Eric Baum, et al.
Journal of Drugs in Dermatology : JDD|October 3, 2013
Adherence to ustekinumab in psoriasis patientsLaura F Sandoval, Karen E Huang, Steven R Feldman
Expert Opinion on Pharmacotherapy|November 17, 2020
An update on the impact of depression on the treatment of psoriasisKatheryn A Bell, Esther A Balogh, Steven R Feldman
Dermatology Online Journal|January 11, 2021
The dermatology residency application processSree S Kolli, Steven R Feldman, William W Huang
Dermatology and Therapy|June 10, 2021
Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of SecukinumabKatherine Houghton, Dhaval Patil, Braulio Gomez, et al.
Journal of the American Academy of Dermatology|February 8, 2020
The bandwagon effect increases acne treatment willingness in teenagersJeremy K Bray, E J Masicampo, Steven R Feldman
The Annals of Pharmacotherapy|May 19, 2022
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic DermatitisPatrick O Perche, Madison K Cook, Steven R Feldman
Journal of the American Academy of Dermatology|June 6, 2024
Atopic dermatitis may not confer clinically meaningful risk of inflammatory bowel disease or renal malignancyHannah Y Gantz, Jonathan D Greenzaid, Steven R Feldman
Clinical, Cosmetic and Investigational Dermatology|January 25, 2021
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque PsoriasisJeremy G Light, Jennifer J Su, Steven R Feldman
Pageof 130